@article{f912eace4afe49c68fe9cacc3883bfd9,
title = "Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician{\textquoteright}s choice of chemotherapy in patients with HER2-low mBC",
keywords = "antibody-drug conjugate, HER2-low, metastatic breast cancer, patient-reported outcomes, quality of life, trastuzumab deruxtecan",
author = "Ueno, \{Naoto T.\} and Francesco Cottone and Kyle Dunton and William Jacot and Toshinari Yamashita and Joohyuk Sohn and Eriko Tokunaga and Aleix Prat and Junji Tsurutani and Park, \{Yeon Hee\} and Rugo, \{Hope S.\} and Binghe Xu and Fatima Cardoso and Zahi Mitri and Reshma Mahtani and Aguilar, \{Cecilia Orbegoso\} and Feng Xiao and Nadia Harbeck and Cameron, \{David A.\} and Shanu Modi",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2025. Published by Oxford University Press.",
year = "2025",
month = may,
day = "1",
doi = "10.1093/oncolo/oyaf048",
language = "English",
volume = "30",
journal = "Oncologist",
issn = "1083-7159",
number = "5",
}